{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:46:51Z","timestamp":1781664411979,"version":"3.54.5"},"reference-count":54,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jid.2018.03.1516","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:08:25Z","timestamp":1522109305000},"page":"1982-1989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg\u00a0Type"],"prefix":"10.1016","volume":"138","author":[{"given":"Marie","family":"Beylot-Barry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Mermin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-B\u00e9n\u00e9dicte","family":"Duval-Modeste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Ingen-Housz-Oro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ram-Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Barete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Maubec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Quereux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Templier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Grange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Vergier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Julien","family":"Vially","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pham-Ledard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Frison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Merlio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2018.03.1516_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620716652861","article-title":"A\u00a0comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"7","author":"Arora","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jid.2018.03.1516_bib2","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2018.03.1516_bib3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"7247","key":"10.1016\/j.jid.2018.03.1516_bib4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jid.2018.03.1516_bib5","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A\u00a0phase 2\/3 multicenter, randomized study comparing the efficacy and safety of lenalidomide versus investigator\u2019s choice in relapsed\/refractory DLBCL","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.jid.2018.03.1516_bib6","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.3324\/haematol.2016.161893","article-title":"Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79","volume":"102","author":"Deng","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jid.2018.03.1516_bib7","first-page":"10705","article-title":"Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis","volume":"8","author":"Fang","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"11","key":"10.1016\/j.jid.2018.03.1516_bib8","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1111\/jdv.14358","article-title":"Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases","volume":"31","author":"Gardette","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2018.03.1516_bib9","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archderm.143.9.1144","article-title":"Primary cutaneous diffuse large b-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases","volume":"143","author":"Grange","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2018.03.1516_bib10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamadermatol.2013.7452","article-title":"Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France","volume":"150","author":"Grange","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2018.03.1516_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archdermatol.2009.23","article-title":"Treatment of cutaneous b-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab","volume":"145","author":"Grange","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2018.03.1516_bib12","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood-2003-08-2726","article-title":"Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas","volume":"103","author":"Grange","year":"2004","journal-title":"Blood"},{"issue":"6067","key":"10.1016\/j.jid.2018.03.1516_bib13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4081\/rt.2015.6067","article-title":"Excellent outcome of immunomodulation or Bruton\u2019s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"7","author":"Gupta","year":"2015","journal-title":"Rare Tumors"},{"key":"10.1016\/j.jid.2018.03.1516_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archdermatol.2009.345","article-title":"Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients","volume":"146","author":"Guyot","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2018.03.1516_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2340\/00015555-1112","article-title":"Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study","volume":"91","author":"Hallermann","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2018.03.1516_bib16","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell\u2013like than in germinal center B-cell\u2013like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jid.2018.03.1516_bib17","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/modpathol.3800650","article-title":"Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma","volume":"19","author":"Hoefnagel","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jid.2018.03.1516_bib18","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.3109\/10428194.2014.889822","article-title":"Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"55","author":"Ivanov","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jid.2018.03.1516_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2018.03.1516_bib20","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.jid.2017.06.013","article-title":"Novel mutations involving NF-\u03baB and B-cell signaling pathways in primary cutaneous large B-cell lymphoma, leg-type and comparison with S\u00e9zary syndrome","volume":"137","author":"Kim","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2018.03.1516_bib21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jid.2018.03.1516_bib22","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood-2005-03-1175","article-title":"Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients","volume":"106","author":"Kodama","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jid.2018.03.1516_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/jid.2013.265","article-title":"Nuclear factor-\u03baB pathway\u2013activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type","volume":"134","author":"Koens","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2018.03.1516_bib24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/ijc.21805","article-title":"Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin\u2019s lymphoma","volume":"119","author":"Leonard","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2018.03.1516_bib25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jid.2018.03.1516_bib26","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.jid.2017.04.010","article-title":"Identification of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, leg type by massive parallel sequencing","volume":"137","author":"Mareschal","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2018.03.1516_bib27","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.jid.2016.04.018","article-title":"MYD88 somatic mutation is a diagnostic criterion in primary cutaneous large B-cell lymphoma","volume":"136","author":"Menguy","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2018.03.1516_bib28","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1634\/theoncologist.2016-0103","article-title":"Lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: is it a valid treatment option?","volume":"21","author":"Mondello","year":"2016","journal-title":"Oncologist"},{"issue":"7332","key":"10.1016\/j.jid.2018.03.1516_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jid.2018.03.1516_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non\u2013germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2018.03.1516_bib31","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2014.821","article-title":"High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large b-cell lymphoma, leg-type","volume":"150","author":"Pham-Ledard","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2018.03.1516_bib32","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/jid.2012.102","article-title":"MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"132","author":"Pham-Ledard","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2018.03.1516_bib33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/modpathol.2013.156","article-title":"Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma","volume":"27","author":"Pham-Ledard","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jid.2018.03.1516_bib34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00277-013-1787-0","article-title":"Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type","volume":"93","author":"Savini","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jid.2018.03.1516_bib35","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","article-title":"Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO\u2013EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers","volume":"25","author":"Senff","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2018.03.1516_bib36","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/archderm.143.12.1520","article-title":"Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification","volume":"143","author":"Senff","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2018.03.1516_bib37","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jid.2018.03.1516_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jid.2018.03.1516_bib39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00277-014-2253-3","article-title":"Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type","volume":"94","author":"Swaika","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jid.2018.03.1516_bib40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/sj.bjc.6600199","article-title":"A\u00a0Bayesian re-assessment of two phase II trials of gemcitabine in metastatic nasopharyngeal cancer","volume":"86","author":"Tan","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jid.2018.03.1516_bib41","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2018.03.1516_bib42","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archderm.1996.03890350042008","article-title":"Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group","volume":"132","author":"Vermeer","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2018.03.1516_bib43","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jid.2018.03.1516_bib44","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2018.03.1516_bib45","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jid.2018.03.1516_bib46","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2018.03.1516_bib47","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdv102","article-title":"A\u00a0comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma","volume":"26","author":"Witzig","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jid.2018.03.1516_bib48","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jid.2018.03.1516_bib49","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jid.2018.03.1516_bib50","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jid.2018.03.1516_bib51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/hon.2049","article-title":"Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed\/refractory diffuse large B-cell lymphoma patients: lenalidomide and rituximab in elderly DLBCL patients","volume":"31","author":"Zinzani","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jid.2018.03.1516_bib52","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","article-title":"Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial","volume":"11","author":"Zinzani","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jid.2018.03.1516_bib53","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3109\/10428194.2014.964702","article-title":"Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice","volume":"56","author":"Zinzani","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jid.2018.03.1516_bib54","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/10428194.2016.1184755","article-title":"The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study","volume":"58","author":"Zinzani","year":"2017","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18318074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18318074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T21:10:40Z","timestamp":1567285840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X18318074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0022202X18318074"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2018.03.1516","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg\u00a0Type","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2018.03.1516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}